Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer: A multi‐institutional collaborative study
Objectives To validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer and provide a more accurate stratification model for a heterogeneous intermediate‐risk group. Methods A total of 1610 patients, who underwent tra...
Saved in:
Published in | International journal of urology Vol. 30; no. 5; pp. 473 - 481 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
Wiley Subscription Services, Inc
01.05.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objectives
To validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer and provide a more accurate stratification model for a heterogeneous intermediate‐risk group.
Methods
A total of 1610 patients, who underwent transurethral resection, diagnosed with non‐muscle invasive bladder cancer in nine collaborating hospitals were retrospectively reviewed. They were classified into low‐risk, intermediate‐risk, high‐risk, and highest‐risk groups, and recurrence‐free survival, progression‐free survival, cancer‐specific survival, and overall survival were compared among the groups. The intermediate‐risk group was subdivided into two groups based on the multivariable Cox regression model of recurrence and progression risk factors, and a revised risk model was created.
Results
The progression‐free survival, cancer‐specific survival, and overall survival were well stratified, while the recurrence‐free survival of the intermediate‐risk group was the shortest among the four groups (p < 0.001). The independent risk factors for recurrence and progression‐free survival in the intermediate‐risk group were as follows: age ≥ 70 years, sex, multiple tumors, tumor size ≥3 cm, and recurrent cases. The intermediate‐risk group was subdivided into two groups: favorable intermediate‐risk group and unfavorable intermediate‐risk group. The revised risk model showed significant differences.
Conclusion
We validated the Japanese Urological Association guidelines 2019 stratification model. The revised risk model provided a more accurate treatment selection for this disease subset. |
---|---|
AbstractList | Objectives
To validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer and provide a more accurate stratification model for a heterogeneous intermediate‐risk group.
Methods
A total of 1610 patients, who underwent transurethral resection, diagnosed with non‐muscle invasive bladder cancer in nine collaborating hospitals were retrospectively reviewed. They were classified into low‐risk, intermediate‐risk, high‐risk, and highest‐risk groups, and recurrence‐free survival, progression‐free survival, cancer‐specific survival, and overall survival were compared among the groups. The intermediate‐risk group was subdivided into two groups based on the multivariable Cox regression model of recurrence and progression risk factors, and a revised risk model was created.
Results
The progression‐free survival, cancer‐specific survival, and overall survival were well stratified, while the recurrence‐free survival of the intermediate‐risk group was the shortest among the four groups (p < 0.001). The independent risk factors for recurrence and progression‐free survival in the intermediate‐risk group were as follows: age ≥ 70 years, sex, multiple tumors, tumor size ≥3 cm, and recurrent cases. The intermediate‐risk group was subdivided into two groups: favorable intermediate‐risk group and unfavorable intermediate‐risk group. The revised risk model showed significant differences.
Conclusion
We validated the Japanese Urological Association guidelines 2019 stratification model. The revised risk model provided a more accurate treatment selection for this disease subset. To validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer and provide a more accurate stratification model for a heterogeneous intermediate-risk group. A total of 1610 patients, who underwent transurethral resection, diagnosed with non-muscle invasive bladder cancer in nine collaborating hospitals were retrospectively reviewed. They were classified into low-risk, intermediate-risk, high-risk, and highest-risk groups, and recurrence-free survival, progression-free survival, cancer-specific survival, and overall survival were compared among the groups. The intermediate-risk group was subdivided into two groups based on the multivariable Cox regression model of recurrence and progression risk factors, and a revised risk model was created. The progression-free survival, cancer-specific survival, and overall survival were well stratified, while the recurrence-free survival of the intermediate-risk group was the shortest among the four groups (p < 0.001). The independent risk factors for recurrence and progression-free survival in the intermediate-risk group were as follows: age ≥ 70 years, sex, multiple tumors, tumor size ≥3 cm, and recurrent cases. The intermediate-risk group was subdivided into two groups: favorable intermediate-risk group and unfavorable intermediate-risk group. The revised risk model showed significant differences. We validated the Japanese Urological Association guidelines 2019 stratification model. The revised risk model provided a more accurate treatment selection for this disease subset. ObjectivesTo validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer and provide a more accurate stratification model for a heterogeneous intermediate‐risk group.MethodsA total of 1610 patients, who underwent transurethral resection, diagnosed with non‐muscle invasive bladder cancer in nine collaborating hospitals were retrospectively reviewed. They were classified into low‐risk, intermediate‐risk, high‐risk, and highest‐risk groups, and recurrence‐free survival, progression‐free survival, cancer‐specific survival, and overall survival were compared among the groups. The intermediate‐risk group was subdivided into two groups based on the multivariable Cox regression model of recurrence and progression risk factors, and a revised risk model was created.ResultsThe progression‐free survival, cancer‐specific survival, and overall survival were well stratified, while the recurrence‐free survival of the intermediate‐risk group was the shortest among the four groups (p < 0.001). The independent risk factors for recurrence and progression‐free survival in the intermediate‐risk group were as follows: age ≥ 70 years, sex, multiple tumors, tumor size ≥3 cm, and recurrent cases. The intermediate‐risk group was subdivided into two groups: favorable intermediate‐risk group and unfavorable intermediate‐risk group. The revised risk model showed significant differences.ConclusionWe validated the Japanese Urological Association guidelines 2019 stratification model. The revised risk model provided a more accurate treatment selection for this disease subset. Abstract Objectives To validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer and provide a more accurate stratification model for a heterogeneous intermediate‐risk group. Methods A total of 1610 patients, who underwent transurethral resection, diagnosed with non‐muscle invasive bladder cancer in nine collaborating hospitals were retrospectively reviewed. They were classified into low‐risk, intermediate‐risk, high‐risk, and highest‐risk groups, and recurrence‐free survival, progression‐free survival, cancer‐specific survival, and overall survival were compared among the groups. The intermediate‐risk group was subdivided into two groups based on the multivariable Cox regression model of recurrence and progression risk factors, and a revised risk model was created. Results The progression‐free survival, cancer‐specific survival, and overall survival were well stratified, while the recurrence‐free survival of the intermediate‐risk group was the shortest among the four groups ( p < 0.001). The independent risk factors for recurrence and progression‐free survival in the intermediate‐risk group were as follows: age ≥ 70 years, sex, multiple tumors, tumor size ≥3 cm, and recurrent cases. The intermediate‐risk group was subdivided into two groups: favorable intermediate‐risk group and unfavorable intermediate‐risk group. The revised risk model showed significant differences. Conclusion We validated the Japanese Urological Association guidelines 2019 stratification model. The revised risk model provided a more accurate treatment selection for this disease subset. |
Author | Miyake, Hideaki Fujii, Tomomi Kinjyo, Mitsuru Shimokama, Tatsuro Nakagawa, Masayuki Iida, Kouta Shimada, Keiji Enokida, Hideki Matsumoto, Hiroaki Matsuyama, Hideyasu Miyake, Makito Yonemori, Masaya Matsushita, Yuto Miyamoto, Tatsuki Nakahama, Tomonori Onishi, Kenta Okumura, Koji Fujimoto, Kiyohide Nishimura, Nobutaka Baba, Satoshi |
Author_xml | – sequence: 1 givenname: Tatsuki orcidid: 0000-0002-0065-881X surname: Miyamoto fullname: Miyamoto, Tatsuki organization: Nara Medical University – sequence: 2 givenname: Makito orcidid: 0000-0001-9503-7356 surname: Miyake fullname: Miyake, Makito email: makitomiyake@yahoo.co.jp organization: Nara Medical University – sequence: 3 givenname: Tomonori surname: Nakahama fullname: Nakahama, Tomonori organization: Nara Medical University – sequence: 4 givenname: Nobutaka surname: Nishimura fullname: Nishimura, Nobutaka organization: Nara Medical University – sequence: 5 givenname: Kenta surname: Onishi fullname: Onishi, Kenta organization: Nara Medical University – sequence: 6 givenname: Kouta orcidid: 0000-0001-7804-9128 surname: Iida fullname: Iida, Kouta organization: Nara Medical University – sequence: 7 givenname: Masaya surname: Yonemori fullname: Yonemori, Masaya organization: Kagoshima University – sequence: 8 givenname: Hideki surname: Enokida fullname: Enokida, Hideki organization: Kagoshima University – sequence: 9 givenname: Masayuki surname: Nakagawa fullname: Nakagawa, Masayuki organization: Kagoshima University – sequence: 10 givenname: Hiroaki orcidid: 0000-0003-0568-1258 surname: Matsumoto fullname: Matsumoto, Hiroaki organization: Yamaguchi University – sequence: 11 givenname: Hideyasu surname: Matsuyama fullname: Matsuyama, Hideyasu organization: Yamaguchi University – sequence: 12 givenname: Yuto orcidid: 0000-0002-8159-9793 surname: Matsushita fullname: Matsushita, Yuto organization: Hamamatsu University of Medicine – sequence: 13 givenname: Hideaki orcidid: 0000-0002-9430-7518 surname: Miyake fullname: Miyake, Hideaki organization: Hamamatsu University of Medicine – sequence: 14 givenname: Tomomi surname: Fujii fullname: Fujii, Tomomi organization: Nara Medical University – sequence: 15 givenname: Keiji surname: Shimada fullname: Shimada, Keiji organization: Nara City Hospital – sequence: 16 givenname: Satoshi surname: Baba fullname: Baba, Satoshi organization: Hamamatsu University of Medicine – sequence: 17 givenname: Mitsuru surname: Kinjyo fullname: Kinjyo, Mitsuru organization: Steel Memorial Yawata Hospital – sequence: 18 givenname: Tatsuro surname: Shimokama fullname: Shimokama, Tatsuro organization: Steel Memorial Yawata Hospital – sequence: 19 givenname: Koji surname: Okumura fullname: Okumura, Koji organization: Steel Memorial Yawata Hospital – sequence: 20 givenname: Kiyohide orcidid: 0000-0003-1507-2464 surname: Fujimoto fullname: Fujimoto, Kiyohide organization: Nara Medical University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36788781$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU9u1DAchS1URKeFBRdAltjAIq3tJHbMblTxp1UlNgzbyHF-Lh4ce7DjVrPjCByJs3ASPE1hgYQ3luzvfXrSO0FHPnhA6DklZ7Scc7vNZ7SlnD1CK9o0rGKkYUdoRSSVVUcFO0YnKW0JoTWj3RN0XHPRdaKjK_Tzs3J2VLMNHgeD5y-Ao01fcZpjeTRWL18e7twej2CshxFbfw9eqZ3ykABvYnDhprAOr1MK2i6hm2xHcCWRMCNUYhMiLs1_ff8x5aQdFM-tSvYW8ODUOELEWnkN8Q1e4ym72RbS-jTbOR98xa6Dc2oIh2olleY87p-ix0a5BM8e7lO0eff208WH6vrj-8uL9XWlm6Zm1SA1dFyqUQGXZlCcDqI1jAFnjVZcdVqZoR4op9QoJrXgqpUdrZWoqWhaVZ-iV4t3F8O3DGnuJ5s0lD4eQk49E0IQShrSFvTlP-g25Fj6F6qjDW_bWspCvV4oHUNKEUy_i3ZScd9T0h9m7cus_f2shX3xYMzDBONf8s-OBThfgDvrYP9_U395tVmUvwFcX7Qu |
CitedBy_id | crossref_primary_10_1002_bco2_305 crossref_primary_10_1111_iju_15286 crossref_primary_10_1111_iju_15177 crossref_primary_10_1111_iju_15474 crossref_primary_10_1007_s11255_023_03851_3 |
Cites_doi | 10.1111/j.1464-410X.2010.09850.x 10.1007/s10147-020-01654-5 10.1016/j.eururo.2016.02.028 10.1111/iju.14281 10.1016/j.eururo.2005.12.031 10.1016/j.juro.2014.02.2573 10.1111/iju.14210 10.1016/j.eururo.2012.10.039 10.1111/j.1442-2042.2008.02235.x 10.3322/caac.21492 10.1111/bju.13760 10.1016/j.euf.2020.05.004 10.1200/JCO.2005.05.1771 10.1016/j.juro.2016.06.049 |
ContentType | Journal Article |
Copyright | 2023 The Japanese Urological Association. 2023 The Japanese Urological Association |
Copyright_xml | – notice: 2023 The Japanese Urological Association. – notice: 2023 The Japanese Urological Association |
CorporateAuthor | Nishinihon Uro-oncology Extensive Collaboration group Nishinihon Uro‐oncology Extensive Collaboration group |
CorporateAuthor_xml | – name: Nishinihon Uro-oncology Extensive Collaboration group – name: Nishinihon Uro‐oncology Extensive Collaboration group |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7X8 |
DOI | 10.1111/iju.15162 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE Calcium & Calcified Tissue Abstracts MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1442-2042 |
EndPage | 481 |
ExternalDocumentID | 10_1111_iju_15162 36788781 IJU15162 |
Genre | researchArticle Validation Study Multicenter Study Journal Article |
GrantInformation_xml | – fundername: JSPS KAKENHI funderid: 16K20159; 26861290 – fundername: Fiscal Years 2015–2016 Nara Medical University Grant‐in‐Aid for Collaborative Research Projects – fundername: JSPS KAKENHI grantid: 16K20159 – fundername: JSPS KAKENHI grantid: 26861290 – fundername: Fiscal Years 2015-2016 Nara Medical University Grant-in-Aid for Collaborative Research Projects |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OB 1OC 29J 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBC EBD EBS EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH YUY ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7X8 |
ID | FETCH-LOGICAL-c4432-b9ce869adae69fba61b75f22e624ca6a8cafb3b1611fa29c76a59813a731745a3 |
IEDL.DBID | DR2 |
ISSN | 0919-8172 |
IngestDate | Fri Aug 16 07:54:37 EDT 2024 Fri Sep 13 06:45:21 EDT 2024 Fri Aug 23 03:04:45 EDT 2024 Sat Sep 28 08:08:56 EDT 2024 Sat Aug 24 00:54:17 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | non-muscle invasive bladder cancer Japanese Urological Association intermediate risk risk stratification European Association of Urology |
Language | English |
License | 2023 The Japanese Urological Association. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4432-b9ce869adae69fba61b75f22e624ca6a8cafb3b1611fa29c76a59813a731745a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-0065-881X 0000-0001-9503-7356 0000-0002-8159-9793 0000-0003-0568-1258 0000-0002-9430-7518 0000-0003-1507-2464 0000-0001-7804-9128 |
PMID | 36788781 |
PQID | 2814655399 |
PQPubID | 2045142 |
PageCount | 482 |
ParticipantIDs | proquest_miscellaneous_2777010405 proquest_journals_2814655399 crossref_primary_10_1111_iju_15162 pubmed_primary_36788781 wiley_primary_10_1111_iju_15162_IJU15162 |
PublicationCentury | 2000 |
PublicationDate | May 2023 |
PublicationDateYYYYMMDD | 2023-05-01 |
PublicationDate_xml | – month: 05 year: 2023 text: May 2023 |
PublicationDecade | 2020 |
PublicationPlace | Australia |
PublicationPlace_xml | – name: Australia – name: Hoboken |
PublicationTitle | International journal of urology |
PublicationTitleAlternate | Int J Urol |
PublicationYear | 2023 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2017; 119 2011; 107 2006; 24 2020 2006; 49 2013; 63 2020; 27 2019 2020; 25 2016; 70 2014; 192 2009; 16 2016; 196 2018; 68 36924311 - Int J Urol. 2023 May;30(5):481-482 e_1_2_14_2_1 e_1_2_14_4_1 e_1_2_14_3_1 e_1_2_14_11_1 e_1_2_14_10_1 e_1_2_14_13_1 e_1_2_14_12_1 e_1_2_14_15_1 e_1_2_14_14_1 e_1_2_14_17_1 e_1_2_14_16_1 e_1_2_14_6_1 e_1_2_14_5_1 e_1_2_14_8_1 e_1_2_14_7_1 e_1_2_14_9_1 |
References_xml | – volume: 70 start-page: 106 year: 2016 end-page: 19 article-title: The 2016 WHO classification of tumors of the urinary system and male genital organs‐part B: prostate and bladder tumors publication-title: Eur Urol – volume: 49 start-page: 466 year: 2006 end-page: 75 article-title: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials publication-title: Eur Urol – volume: 68 start-page: 394 year: 2018 end-page: 424 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin – volume: 107 start-page: 1598 year: 2011 end-page: 604 article-title: Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumors: validation study on the European Association of Urology guidelines publication-title: Int BJU – volume: 27 start-page: 362 year: 2020 end-page: 8 article-title: Clinical practice guidelines for bladder cancer 2019 edition by the Japanese Urological Association: revision working position paper publication-title: Int J Urol – volume: 16 start-page: 279 year: 2009 end-page: 86 article-title: Clinical outcome of tumor recurrence for Ta, T1 non‐muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999–2001 report from the Japanese Urological Association publication-title: Int J Urol – volume: 196 start-page: 1021 year: 2016 end-page: 9 article-title: Diagnosis and treatment of non‐muscle invasive bladder cancer: AUA/SUO guideline publication-title: J Urol – year: 2020 article-title: Stratification of intermediate‐risk non‐muscle‐invasive Badder cancer patients: implication for Ajuvant therapies publication-title: Eur Urol – volume: 27 start-page: 702 year: 2020 end-page: 9 article-title: Clinical practice guidelines for bladder cancer 2019 update by the Japanese Urological Association: summary of the revision publication-title: Int J Urol – volume: 24 start-page: 3664 year: 2006 end-page: 71 article-title: Prospective study of FGFR3 mutations as a prognostic factor in non‐muscle invasive urothelial bladder carcinomas publication-title: J Clin Oncol – volume: 25 start-page: 1364 year: 2020 end-page: 76 article-title: A new risk stratification model for intravesical recurrence, disease progression, and cancer‐specific death in patients with non‐muscle invasive bladder cancer: the J‐NICE risk tables publication-title: Int J Clin Oncol – volume: 192 start-page: 305 year: 2014 end-page: 15 article-title: Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer publication-title: J Urol – year: 2019 – volume: 119 start-page: 371 year: 2017 end-page: 80 article-title: Guideline of guidelines: non‐muscle invasive bladder cancer publication-title: BJU Int – volume: 63 start-page: 462 year: 2013 end-page: 72 article-title: Final results of an EORTC‐GU cancers group randomized study of maintenance bacillus Calmette‐Guerin in intermediate‐ and high‐risk Ta, T1 papillary carcinoma of the urinary bladder: one‐third dose versus full dose and 1 year versus 3 years of maintenance publication-title: Eur Urol – ident: e_1_2_14_8_1 doi: 10.1111/j.1464-410X.2010.09850.x – ident: e_1_2_14_7_1 doi: 10.1007/s10147-020-01654-5 – ident: e_1_2_14_9_1 doi: 10.1016/j.eururo.2016.02.028 – ident: e_1_2_14_11_1 – ident: e_1_2_14_5_1 doi: 10.1111/iju.14281 – ident: e_1_2_14_13_1 doi: 10.1016/j.eururo.2005.12.031 – ident: e_1_2_14_16_1 doi: 10.1016/j.juro.2014.02.2573 – ident: e_1_2_14_4_1 doi: 10.1111/iju.14210 – ident: e_1_2_14_15_1 doi: 10.1016/j.eururo.2012.10.039 – ident: e_1_2_14_6_1 doi: 10.1111/j.1442-2042.2008.02235.x – ident: e_1_2_14_2_1 doi: 10.3322/caac.21492 – ident: e_1_2_14_3_1 doi: 10.1111/bju.13760 – ident: e_1_2_14_17_1 doi: 10.1016/j.euf.2020.05.004 – ident: e_1_2_14_12_1 – ident: e_1_2_14_14_1 doi: 10.1200/JCO.2005.05.1771 – ident: e_1_2_14_10_1 doi: 10.1016/j.juro.2016.06.049 |
SSID | ssj0013218 |
Score | 2.4072618 |
Snippet | Objectives
To validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer and... To validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer and provide a... Abstract Objectives To validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder... ObjectivesTo validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer and... OBJECTIVESTo validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer and... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 473 |
SubjectTerms | Aged Bladder cancer Cancer Disease Progression East Asian People European Association of Urology Humans intermediate risk Invasiveness Japanese Urological Association Neoplasm Invasiveness - pathology Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - prevention & control Non-Muscle Invasive Bladder Neoplasms non‐muscle invasive bladder cancer Retrospective Studies Risk Assessment Risk factors Risk groups risk stratification Survival Urinary Bladder Neoplasms - pathology |
Title | Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer: A multi‐institutional collaborative study |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fiju.15162 https://www.ncbi.nlm.nih.gov/pubmed/36788781 https://www.proquest.com/docview/2814655399/abstract/ https://search.proquest.com/docview/2777010405 |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbhMxFLWqLio2QHkOFHRBLNhMlPH4MS6rClGVSGWBCOoCaWR7bBQoCUoySLDqJ_BJfAtfwr2emSgFISF2kWLHnvF9HF-fHDP2RFg_VpXDvUnQPBeYkPJKRlLd5zyGMtgyHcWcvlInUzE5k2c77NnwX5hOH2JTcCPPSPGaHNy61ZaTzz60I0xXKf6SkB4Botd86wQh1fYwHVKZS_NeVYhYPJuel3PRHwDzMl5NCef4Gns3TLXjmXwctWs38t9-U3H8z2e5zq72QBSOOsvZZzthfoPtnfZH7TfZj7eI0LsLl2ARAXEiEA0dOp3d2Jf6AFH5-VdoQsRODczmqeEEMzDdbAnT5RBbYcsO4H1L4lpEuAdEBgYQOMN8Mf958f1Tu8LZ4O98scSrB3dOkXEJnoxzeQhHkBiQ2HLWsxxSKRO2zBl7Jc3cW2x6_OLN85O8v-4h90KUPHfGh0oZ29igTHRWFU7LyHlQXHirbOVtdKVDiFpEy43XykpTFaXViIGEtOVttotzDXcZjOXYVhiaKmmM4CLYQpnQaOO5M1Y0PmOPh4WvP3eqHvWwG8K1qNNaZOxgMIm6d-xVzalkKknON2OPNl-jS9I5C77aRYtttNa0zR3LjN3pTGkzSqmIvlkVGXuaDOLvw9cvJ9P04d6_N73PrnAEYR0h84DtrpdteICgae0eJu_4BRVUF6o |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFD6ahgTc8M8IDDggLrhJ1Ti2EyNuJsTUlXUXaEW7QZHt2KgwWtQ1SHDFI_BIPAtPwrGTVB0ICXFXqXbtxOfn8_HXzwBPuLZDWRram7iCpZwSUloKH1T3GfMudzqPRzGTIzma8vGJONmC5_1_YVp9iHXBLXhGjNfBwUNBesPLZ--bAeWrEIAvkLuLuKF6zTbOEGJ1jxJiKHQVrNMVCjyeddfz2egPiHkescaUs38V3vaTbZkmHwbNygzs1990HP_3aa7BlQ6L4l5rPNdhy81vwMVJd9p-E368IZDe3rmEC48EFTEw0bGV2vVdtQ8JmJ9-wdp56lTjbB4bjikJh8stcbrswytumAK-a4K-VuDcI4EDhYSdcb6Y__z2_WNzRrOh3_msA7UezWkIjku0wT6Xz3APIwmSWs46okOsZuKGRVOvKJt7C6b7L49fjNLuxofUcp6z1CjrSql0rZ1U3miZmUJ4xpxk3GqpS6u9yQ2h1MxrpmwhtVBlluuCYBAXOr8N2zRXdwdwKIa6pOhUCqU4405nUrm6UJYZpXltE3jcr3z1qRX2qPoNEa1FFdcigd3eJqrOt88qFqqmIij6JvBo_TV5ZThqoVe7aKhNURRhpzsUCey0trQeJZeBwVlmCTyNFvH34auD8TR-uPvvTR_CpdHx5LA6PDh6dQ8uM8JkLT9zF7ZXy8bdJwy1Mg-iq_wCfNMbzA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFD6ahjRxwz8sMOCAuOAmVeM4dgxXE6PaCpsQomgXSJHt2Kgw2qlrkOCKR-CReBaehGMnqToQEuKuUu3aic_P5-OvnwEecW2HojS0N3GSpZwSUloWPqjuM-Zd7nQej2IOj8T-hI-Pi-MNeNr_F6bVh1gV3IJnxHgdHPy09mtOPv3QDChdhfh7gYucBZPee83WjhBicY_yYahzSdbJCgUaz6rr-WT0B8I8D1hjxhldhnf9XFuiycdBszQD-_U3Gcf_fJgrcKlDorjbms5V2HCza7B12J21X4cfbwmitzcu4dwjAUUMPHRshXZ9V-tDguUnX7B2njrVOJ3FhmNKweFqS5ws-uCKa4aA75ugrhUY90jQQCEhZ5zNZz-_ff_UnNFs6Hc-60CsR3MSQuMCbbDOxRPcxUiBpJbTjuYQa5m4Zs_UK4rm3oDJ6PmbZ_tpd99DajnPWWqUdaVQutZOKG-0yIwsPGNOMG610KXV3uSGMGrmNVNWCl2oMsu1JBDEC53fhE2aq9sGHBZDXVJsKgulOONOZ0K5WirLjNK8tgk87Be-Om1lPap-O0RrUcW1SGCnN4mq8-yzioWaaRH0fBN4sPqafDIctNCrnTfURkoZ9rnDIoFbrSmtRslF4G-WWQKPo0H8ffjqYDyJH27_e9P7sPVqb1S9PDh6cQcuMgJkLTlzBzaXi8bdJQC1NPeio_wCJw8aew |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Validation+of+the+risk+stratification+newly+defined+in+the+Japanese+Urological+Association+guidelines+2019+for+non%E2%80%90muscle+invasive+bladder+cancer%3A+A+multi%E2%80%90institutional+collaborative+study&rft.jtitle=International+journal+of+urology&rft.au=Miyamoto%2C+Tatsuki&rft.au=Miyake%2C+Makito&rft.au=Nakahama%2C+Tomonori&rft.au=Nishimura%2C+Nobutaka&rft.date=2023-05-01&rft.issn=0919-8172&rft.eissn=1442-2042&rft.volume=30&rft.issue=5&rft.spage=473&rft.epage=481&rft_id=info:doi/10.1111%2Fiju.15162&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_iju_15162 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0919-8172&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0919-8172&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0919-8172&client=summon |